NASDAQ:IONS - Ionis Pharmaceuticals Stock Price, Price Target & More

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Ionis Pharmaceuticals Inc (NASDAQ:IONS) posted its quarterly earnings data on Friday, May, 4th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.11) by $0.10. The company had revenue of $144.40 million for the quarter, compared to the consensus estimate of $144.01 million. Ionis Pharmaceuticals had a negative net margin of 2.00% and a negative return on equity of 3.06%. The firm's revenue was up 24.7% compared to the same quarter last year. During the same period last year, the company earned $0.03 earnings per share. View Ionis Pharmaceuticals' Earnings History.

11 analysts have issued 12-month price targets for Ionis Pharmaceuticals' shares. Their forecasts range from $18.00 to $75.00. On average, they expect Ionis Pharmaceuticals' stock price to reach $53.00 in the next year. View Analyst Ratings for Ionis Pharmaceuticals.

Ionis Pharmaceuticals saw a increase in short interest in May. As of May 15th, there was short interest totalling 12,158,108 shares, an increase of 15.8% from the April 30th total of 10,497,036 shares. Based on an average trading volume of 1,696,916 shares, the days-to-cover ratio is currently 7.2 days. Approximately 9.8% of the company's shares are sold short. View Ionis Pharmaceuticals' Current Options Chain.

Some companies that are related to Ionis Pharmaceuticals include Mylan (MYL), BioMarin Pharmaceutical (BMRN), GRIFOLS S A/S (GRFS), UCB (UCBJF), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Nektar Therapeutics (NKTR), Genmab A/S (GNMSF), BeiGene (BGNE), Valeant Pharmaceuticals Intl (VRX) and SAGE Therapeutics (SAGE).

Media stories about IONS stock have been trending somewhat negative this week, Accern Sentiment Analysis reports. Accern rates the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ionis Pharmaceuticals earned a coverage optimism score of -0.07 on Accern's scale. They also assigned news headlines about the company an impact score of 46.89 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Ionis Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BB Biotech AG (6.79%), BlackRock Inc. (5.52%), Baillie Gifford & Co. (4.99%), OppenheimerFunds Inc. (2.29%), Pinnacle Associates Ltd. (0.99%) and American Century Companies Inc. (0.94%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Ionis Pharmaceuticals Inc, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Sarah Boyce and Stanley T Crooke. View Institutional Ownership Trends for Ionis Pharmaceuticals.

IONS stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., JPMorgan Chase & Co., Van ECK Associates Corp, Pinnacle Associates Ltd., BlackRock Inc., Fiera Capital Corp, Altrinsic Global Advisors LLC and A.R.T. Advisors LLC. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Sarah Boyce and Stanley T Crooke. View Insider Buying and Selling for Ionis Pharmaceuticals.

IONS stock was purchased by a variety of institutional investors in the last quarter, including Summit Trail Advisors LLC, BB Biotech AG, Scout Investments Inc., Sector Gamma AS, Carillon Tower Advisers Inc., OppenheimerFunds Inc., UBS Group AG and Millennium Management LLC. View Insider Buying and Selling for Ionis Pharmaceuticals.

Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of IONS stock can currently be purchased for approximately $42.95.

Ionis Pharmaceuticals has a market capitalization of $5.29 billion and generates $507.67 million in revenue each year. The company earns $-5,960,000.00 in net income (profit) each year or $0.08 on an earnings per share basis. Ionis Pharmaceuticals employs 547 workers across the globe.

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200.